Fermenta Biotech Limited (BOM:506414)
India · Delayed Price · Currency is INR 312.80
+1.45 (0.47%)
At close: Feb 12, 2026
Fermenta Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 5,437 | 4,695 | 3,357 | 3,499 | 3,985 | 3,773 |
| 5,437 | 4,695 | 3,357 | 3,499 | 3,985 | 3,773 | |
Revenue Growth (YoY) | 27.34% | 39.87% | -4.08% | -12.19% | 5.63% | 28.79% |
Cost of Revenue | 2,147 | 1,734 | 1,534 | 1,698 | 1,670 | 1,440 |
Gross Profit | 3,290 | 2,961 | 1,822 | 1,801 | 2,315 | 2,333 |
Selling, General & Admin | 834.9 | 704.4 | 620.8 | 618.6 | 660.6 | 605.53 |
Other Operating Expenses | 1,238 | 1,109 | 923 | 1,003 | 1,039 | 909.04 |
Operating Expenses | 2,298 | 2,056 | 1,791 | 1,904 | 1,955 | 1,718 |
Operating Income | 992.83 | 905.42 | 31.17 | -103.27 | 359.77 | 615.15 |
Interest Expense | -117.1 | -141.92 | -170.46 | -207.82 | -162.69 | -156.69 |
Interest & Investment Income | 36.63 | 36.63 | 44.77 | 29.42 | 13.16 | 35.52 |
Currency Exchange Gain (Loss) | 46.19 | 46.19 | 12.57 | 21.08 | 29.99 | 25.48 |
Other Non Operating Income (Expenses) | 96.68 | 2.72 | 6.12 | 2.17 | 9.78 | -22.98 |
EBT Excluding Unusual Items | 1,055 | 849.04 | -75.84 | -258.43 | 250.02 | 496.48 |
Impairment of Goodwill | - | - | -74.26 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.59 | - |
Gain (Loss) on Sale of Assets | -49.6 | -49.6 | -3.26 | -3.15 | -0.27 | -1.6 |
Other Unusual Items | -7.16 | 14.79 | 54.09 | -251.6 | 12.81 | 21.42 |
Pretax Income | 1,016 | 832.08 | -98.73 | -513.05 | 269.43 | 516.31 |
Income Tax Expense | 166.55 | 68.05 | 141.36 | 18.27 | 118.83 | 91 |
Earnings From Continuing Operations | 849.77 | 764.03 | -240.09 | -531.32 | 150.61 | 425.3 |
Minority Interest in Earnings | 19.88 | 4.59 | 9.49 | 20.57 | 3.87 | 29.76 |
Net Income | 869.65 | 768.62 | -230.6 | -510.75 | 154.47 | 455.07 |
Net Income to Common | 869.65 | 768.62 | -230.6 | -510.75 | 154.47 | 455.07 |
Net Income Growth | 144.75% | - | - | - | -66.05% | -23.55% |
Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Outstanding (Diluted) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Change (YoY) | 1.65% | 1.04% | 0.06% | -0.50% | -0.01% | 0.04% |
EPS (Basic) | 29.68 | 26.35 | -7.99 | -17.70 | 5.35 | 15.77 |
EPS (Diluted) | 29.54 | 26.35 | -7.99 | -17.70 | 5.33 | 15.69 |
EPS Growth | 140.88% | - | - | - | -66.03% | -23.57% |
Free Cash Flow | - | 187.69 | 861.39 | 756.19 | 63.13 | 73.26 |
Free Cash Flow Per Share | - | 6.43 | 29.83 | 26.20 | 2.18 | 2.53 |
Dividend Per Share | - | 2.500 | 1.250 | 1.250 | 1.250 | 2.500 |
Dividend Growth | - | 100.00% | - | - | -50.00% | -50.00% |
Gross Margin | 60.52% | 63.08% | 54.29% | 51.47% | 58.09% | 61.83% |
Operating Margin | 18.26% | 19.29% | 0.93% | -2.95% | 9.03% | 16.30% |
Profit Margin | 16.00% | 16.37% | -6.87% | -14.59% | 3.88% | 12.06% |
Free Cash Flow Margin | - | 4.00% | 25.66% | 21.61% | 1.58% | 1.94% |
EBITDA | 1,217 | 1,133 | 262.68 | 161.4 | 591.74 | 796.7 |
EBITDA Margin | 22.39% | 24.13% | 7.83% | 4.61% | 14.85% | 21.12% |
D&A For EBITDA | 224.49 | 227.5 | 231.52 | 264.67 | 231.96 | 181.55 |
EBIT | 992.83 | 905.42 | 31.17 | -103.27 | 359.77 | 615.15 |
EBIT Margin | 18.26% | 19.29% | 0.93% | -2.95% | 9.03% | 16.30% |
Effective Tax Rate | 16.39% | 8.18% | - | - | 44.10% | 17.63% |
Revenue as Reported | 5,649 | 4,813 | 3,475 | 3,585 | 4,067 | 3,855 |
Advertising Expenses | - | 43.35 | 26.45 | 29.16 | 24.96 | 19.64 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.